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Background The impact of atrial fibrillation (AF) catheter ablation (CA) on hard clinical endpoints 2 
remains controversial.  3 
Objective Our aim was to conduct a random effect model meta-analysis on efficacy data from high-4 
quality large matched database/registry studies and randomized clinical trials. We compared long-5 
term all-cause mortality, stroke and hospitalization for heart failure in patients undergoing AFCA vs 6 
patients treated with medical therapy alone (rhythm and/or rate control medications) in a general 7 
AF population. 8 
Methods and Results PubMed/MEDLINE and Embase databases were screened and a total of nine 9 
studies were selected (one randomized clinical trial – CABANA – and eight large matched 10 
population studies). A total of 241,372 patients (27,711 in the ablation group, 213,661 in the non-11 
ablation group) were included. After a median follow-up of 3.5 years, AFCA decreased the risk of 12 
mortality (HR 0.62, 95% CI 0.54-0.72; I2 = 54%; number needed to treat – NNT = 28), stroke (HR 13 
0.63, 95% CI 0.56-0.70; I2 = 23%; NNT 59) and hospitalization for heart failure (HR 0.64, 95% CI 14 
0.51-0.80; I2 = 28%; NNT = 33) compared with AF patients treated with medical therapy alone. 15 
Conclusion Based on the currently available efficacy and effectiveness evidence, AFCA 16 
significantly reduces the risk of death, stroke and hospitalization compared to medical therapy 17 
alone.  18 
 19 
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21 
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Abbreviations and acronyms 1 
AADs = anti-arrhythmic drugs 2 
ACR = assumed control risk 3 
AF = atrial fibrillation 4 
AFCA = atrial fibrillation catheter ablation 5 
ARR = absolute risk reduction 6 
CI = confidence interval 7 
HR = hazard ratio 8 
NNT = number needed to treat 9 
RCT = randomized clinical trial 10 




Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice, with a 2 
progressively growing burden due to population aging. Sinus rhythm maintenance (rhythm control), 3 
reflecting the native heart rhythm, may be perceived as the most natural solution compared to just 4 
controlling ventricular rate (rate control). However, in terms of prevention of death, stroke and heart 5 
failure, rate control has been proven to be non-inferior to rhythm control with anti-arrhythmic drugs 6 
(AADs) in pivotal clinical trials 1, 2. This is most likely explained by the side effects and pro-7 
arrhythmic effects related to AADs, together with a relatively low efficacy of these agents in 8 
maintaining sinus rhythm. 9 
Atrial fibrillation catheter ablation (AFCA) has emerged in clinical practice; although few 10 
randomized clinical studies 3, 4 have reported promising outcomes in terms of sinus rhythm 11 
maintenance and safety when compared to AADs, they have singularly failed to demonstrate a 12 
statistically significant impact of the procedure on hard outcomes (mortality, stroke or HF 13 
hospitalization). These studies have however been widely debated, being generally underpowered to 14 
reveal a possible impact on the aforementioned outcomes in patients undergoing AFCA 5 or  15 
affected by crossovers between the study arms 6. On the contrary, evidence from observational 16 
matched databases/registry studies suggest a net benefit of AFCA in terms of hard clinical endpoint 17 
reductions 7, 8. 18 
The present meta-analysis aimed to determine whether AFCA is effective and safe in the general 19 
AF population by assessing its long-term impact on mortality, stroke and hospitalization due to 20 





The present systematic review and meta-analysis were performed in accordance to PRISMA 9 and 2 
MOOSE guidelines 10. 3 
 4 
Search strategy 5 
We screened PubMed/MEDLINE and Embase databases from their inceptions to April 30th 2019, 6 
using the following search terms: (atrial fibrillation OR AF) AND (catheter ablation OR AFCA OR 7 
ablation) AND (Mortality OR death OR stroke OR CVA OR hospitalization) AND (database OR 8 
registry OR registries OR databases OR RCT).  9 
 10 
Study selection and quality assessment 11 
Two investigators (A.S., M.A.) independently reviewed the titles/abstracts and studies to determine 12 
their eligibility based on the inclusion criteria and extracted all the relevant outcomes of interest. 13 
Randomized and non-randomized studies were eligible for inclusion if they (a) compared at least 14 
one hard clinical outcome (mortality, stroke and, since AF is known to mimic heart failure 15 
symptoms and/or trigger heart failure episodes, hospitalization for heart failure) between cohorts of 16 
ablated and non-ablated AF patients (in case of registry studies, only if they provided adjusted risk 17 
estimates); (b) reported risk estimates for the investigated outcomes based on time-to-event data 18 
(hazard ratio – HR); (c) had a median follow-up of at least 2 years, thus focusing on studies 19 
evaluating long-term impact of AFCA on hard clinical outcomes; (d) did not exclusively include 20 
patients with impaired left ventricular ejection fraction. 21 
Risk of bias assessment was performed at the study level using the Cochrane bias risk assessment 22 
tool for RCT and the Newcastle-Ottawa Scale (NOS) for observational studies (Appendix).  23 
 24 
 6 
Statistical analysis 1 
Baseline characteristics of pooled study populations were reported as median values between the 2 
included studies, along with their interquartile range. 3 
Due to the observational nature of most of the studies, a random effect model (inverse-variance 4 
weighting) was adopted. Random effect model meta-analysis gives more conservative estimates 5 
with respect to fixed effect model meta-analysis, since, differently from fixed effect model, it takes 6 
into account the estimated between-study heterogeneity when pooling individual study results. 7 
Meta-analysis of hazard ratio (HR) was performed after logarithmic transformation. The results 8 
with the corresponding 95% confidence interval (CI) were back-transformed and forest plots for the 9 
different outcomes were generated. To investigate potential publication bias, Egger test was used to 10 
identify asymmetry of funnel plot. Heterogeneity across studies was assessed using the Cochran Q 11 
test. Higgins I2 statistics was used to determine the degree of between-study heterogeneity 12 
(I2 < 25%—low, 25–50%—moderate, and >50%—high degree of heterogeneity). In case of high 13 
degree of heterogeneity, meta-regression analysis was performed to assess potential source of 14 
heterogeneity.  15 
For each outcome, absolute risk reduction was calculated by multiplying the meta-analytic HR 16 
(with the corresponding CI) by the assumed control risk (ACR) obtained from the meta-analysis of 17 
the incidence rate of the outcome (expressed as events/person years) in non-ablation cohorts 18 
(Appendix, Figure 1). Number needed to treat (NNT) was derived by dividing 1 by the calculated 19 
absolute risk reduction (ARR), and the resulting number was finally divided by the meta-analytic 20 
median follow-up in order to obtain an estimate normalized to follow-up duration.  21 
P values < 0.05 were considered statistically significant. Statistical analyses were performed with R 22 
version 3.5.0 (R Foundation for Statistical Computing, Vienna, Austria). 23 
24 
 7 
Results  1 
The initial search, by the specified search criteria, identified 1,187 potential studies (Figure 1). 2 
After detailed evaluation, 19 publications were eligible for possible inclusion and, therefore, full 3 
texts reviewed. Four RCTs were excluded since they were specifically conducted in the setting of 4 
heart failure 11-14. Four RCTs were excluded since they did not provide time-to-event risk estimates 5 
(hazard ratio) for the investigated outcomes 15-18. One large registry study was excluded due to the 6 
indirect nature of the comparison between the ablation and non-ablation cohort 19, while a second 7 
was discarded since it did not provide confidence intervals for the adjusted risk estimates of 8 
mortality and stroke 20. 9 
Finally, 9 studies (one RCT – CABANA – and eight large matched population databases/registries) 10 
were included in the analysis 6, 8, 21-28, encompassing 241,372 patients (27,711 in the ablation group, 11 
213,661 in the non ablation-group), with a median follow-up of 3.5 years (Table 1). The baseline 12 
clinical features of the resulting meta-analytic population are summarized in Table 2. Median age 13 
was 64.1 years, with nearly 2:1 male-to-female ratio. The most frequent concurrent comorbid 14 
conditions were hypertension (55.0%), diabetes (17.0%) and coronary artery disease (19.2%). 15 
Baseline heart failure was present in a low percentage of patients (15.3%). A median of 5.2% 16 
patients suffered previous stroke/TIA and 69.8% had high thromboembolic risk (CHA2DS2-VASc 17 
score ≥ 2). CABANA population, with respect to the pooled population derived from non-18 
randomized matched databases, resulted slightly older, with more comorbid conditions and a higher 19 
baseline thromboembolic risk (Table 2). The statistical methods to control confounding in non-20 
randomized matched database are reported in Table 1: 5 studies used propensity score matching, 2 21 
other propensity score techniques (adjustment and weighting) and 1 study used multivariate 22 
regression analysis. 23 
By random effect model meta-analysis, AFCA decreased the risk of mortality (HR 0.62, 95% CI 24 
0.54-0.72; I2 = 54%; NNT 28), stroke (HR 0.63, 95% CI 0.56-0.70; I2 = 23%; NNT 59) and 25 
 8 
hospitalization for heart failure (HR 0.64, 95% CI 0.51-0.80; I2 = 28%; NNT 33) compared with 1 
medically-treated AF patients. One-year estimated absolute risk reduction in mortality, stroke and 2 
hospitalization for heart failure were 1%, 0.5% and 0.8%, respectively.  3 
There was no evidence of publication bias for the outcomes of interest (Egger’s test p value 0.28, 4 
0.65 and 0.46, respectively; funnel plots are reported in the Appendix, Figures 3-5). Significant 5 
heterogeneity was only present in the mortality estimate. Meta-regression analyses excluded 6 
baseline heart failure (p=0.316) as potential source of heterogeneity, while increased age was 7 
significantly associated with a reduced benefit from ablation (p=0.004, Appendix Figure 2). 8 
Considering “treatment received” rather than “intention to treat” analysis from CABANA data, 9 
catheter ablation decreased the risk of mortality by a greater extent (HR 0.60, 95% CI 0.53-0.67; I2 10 






In the present meta-analysis, AFCA was more effective than medical therapy in reducing hard 2 
clinical endpoints, providing a 38% decrease in mortality, 37% decrease in stroke and 36% 3 
reduction in heart failure hospitalization over a median follow-up of 3.5 years. 4 
AFCA is currently a rhythm control option in AF patients who remain symptomatic on adequate 5 
rate control therapy. Conversely, the proven increased efficacy in maintaining sinus rhythm and 6 
safety of AFCA compared to AADs prompts questions regarding a possible favorable prognostic 7 
impact of modern rhythm control strategy, either with AFCA alone or with an hybrid approach 8 
(AFCA+AADs). The Catheter Ablation for Atrial Fibrillation with Heart Failure (CASTLE-AF) 9 
Trial 11 confirmed previous meta-analytic impressions 29, showing that in patients with heart failure, 10 
AFCA reduced the primary endpoint of all-cause-death or hospitalization compared with medical 11 
therapy. Differently, in patients without heart failure, a meta-analysis comparing AFCA vs medical 12 
therapy on published RCTs apparently found no difference in survival between these two strategies 13 
5. However, it should be noted that, in the latter analysis, the included studies were only four, 14 
underpowered for detecting differences in survival (low number of enrolled patients), the follow-up 15 
duration was short (9 to 24 months, median 12 months) and, most importantly, the number of events 16 
investigated extremely low (6 and 7, in the pooled ablation and medical therapy cohorts, 17 
respectively). Recently, Barra et al. 30 also investigated the topic either in RCTs and observational 18 
studies. In their analysis, the authors found a survival benefit of AFCA, but the randomized 19 
evidence was driven by studies performed specifically in the HF setting, concluding that more data 20 
are needed to draw conclusions in the general AF population. More specifically regarding risk of 21 
stroke, a benefit was only seen within the observational studies, while no benefit emerged 22 
considering randomized evidences (however, only 32 stroke events in the pooled cohorts were seen 23 
during the follow-up).  24 
In addition, inclusion of the latest, widest randomized clinical trial surely increases available 25 
 10
knowledge. The CABANA trial 6, in the “intention to treat” analysis, reported no significant 1 
differences neither in the primary outcome (composite of death, disabling stroke, serious bleeding, 2 
or cardiac arrest), nor in mortality between AFCA and medical therapy groups. This result, 3 
however, was likely affected by a significant lower-than-expected overall mortality rate (from the 4 
expected 12% after 3 years to the actual 5% after 4 year) and high treatment crossover (27.5% from 5 
drug therapy to ablation). Moreover, the composite primary outcome of CABANA trial included 6 
bleeding and stroke, which AFCA has no impact on. In fact, as stated by the authors, definitive 7 
conclusions cannot be drawn, especially considering that, on the other side, “treatment received” 8 
analysis suggested a significant reduction in mortality in the AFCA group of 40% (HR 0.60, 95% 9 
CI 0.42-0.80).  10 
Given these premises, our aim was to synthetize high-quality RCT data of AFCA efficacy (deriving 11 
from CABANA) with real-life evidence of AFCA effectiveness (provided by large registry studies), 12 
in terms of hard clinical endpoints (mortality, stroke and hospitalization for heart failure) in a 13 
general AF population. In this sense, our meta-analysis is different from the meta-analysis of Barra 14 
et al. 30 since (1) it excludes studies exclusively enrolling HF patients, in order to draw general 15 
conclusions in the general AF population; (2) it includes the greatest randomized evidence 16 
published so far in the context of AF (CABANA trial 6); (3) it includes recently released 17 
observational data not included in the previous meta-analysis 27, 28. 18 
The meta-analytic estimates indicate that AFCA significantly reduces all three hard clinical 19 
endpoints by nearly 40%. The heterogeneity of the data was high only for mortality (I2 = 63%). 20 
Interestingly, older age was associated with a decrease in AFCA benefit and thus could explain, at 21 
least partly, the increased heterogeneity of the data. Considering “treatment received” instead of 22 
“intention to treat” analysis from CABANA, we appreciated a drop in the total heterogeneity of 23 
mortality data and an increase in the benefit of AFCA. Of note, the efficacy estimate deriving from 24 
patients that actually underwent ablation in CABANA (HR 0.60, 95% CI 0.42-0.80) is highly 25 
comparable to the meta-analytic effectiveness pooled estimate of mortality reduction in AFCA 26 
 11
group for the registry studies (HR 0.60, 95% CI 0.53-0.68; I2 = 43%). 1 
Additional information is conveyed by the calculated NNTs for each outcome of interest, which not 2 
only take into account the magnitude of the benefit of the intervention, but also depend on the rate 3 
of the specific endpoint in the study population. Despite a similar HR for the three outcomes, NNTs 4 
differed between stroke (NNT 59) and the other two endpoints (NNT 28 for mortality, NNT 33 for 5 
hospitalization), reflecting the different pooled incidence rates in the medically treated group 6 
(mortality: 2.70 events/100 person-years; stroke: 1.32 events/100 person-years; hospitalization for 7 
heart failure: 2.41 events/100 person-years) (Figure 4). In this sense, considering the high 8 
proportion of patients in the included meta-analysis at high thromboembolic risk (CHA2DS2-VASc 9 
score > 2: 69.8%), the relatively more limited impact of AFCA on incidence rate of stroke, 10 
compared to the other outcomes, probably reflects the effective anticoagulation strategy of the 11 
medical arm. 12 
In this context, awaiting publication of the Early treatment of Atrial fibrillation for Stroke 13 
prevention (EAST) Trial (ClinicalTrial.gov Identifier: NCT01288352), the present meta-analyses 14 
summarizes the latest efficacy evidence from CABANA and real-world effectiveness data derived 15 
from observational registries comparing AFCA with medical therapy, suggesting promising effects 16 
of the electrophysiological procedure not only in preventing AF recurrences but also in improving 17 
long-term prognosis of AF patients. 18 
 19 
Limitations 20 
First, this study is limited by the heterogeneity of study participants and outcome definitions 21 
between different studies. Moreover, retrospective registry data should be interpreted with caution, 22 
due to their observational nature. Even though matching and multivariable analysis can control 23 
known confounders, residual confounding attributable to unmeasured factors remains a concern. In 24 
addition, retrospective registry data often lacked information regarding the type of AF (paroxysmal 25 
 12
vs persistent) and arrhythmia duration of the included patients, thus precluding possible subgroup 1 
meta-analyses. Finally, it is possible that studies shorter than two years, excluded since the focus of 2 
the present analysis on long-term outcomes, may have contributed additional patients and power to 3 





In the present meta-analysis, based on the CABANA trial and data form eight large matched 2 
registries, AFCA significantly reduces the risk of death, stroke and hospitalization for heart failure 3 
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Figure legends 1 
Figure 1. Flow-chart of the search strategy following PRISMA guidelines. LVEF: left 2 
ventricular ejection fraction; HR: hazard ratio. 3 
 4 
Figure 2. Meta-analysis forest plots. Shown are random-effect hazard ratios for mortality 5 
(a), stroke (b) and hospitalization for heart failure (c) in the included studies.  6 
 7 
Figure 3. Meta-analysis forest plot of mortality (considering treatment received 8 
analysis of CABANA data).  9 
 10 
Figure 4. Impact of atrial fibrillation catheter ablation on hard clinical outcomes. PY: 11 
person-years; NNT: number needed to treat. 12 
